1. Pink Sheet
  2. >>Geography
  3. >>Europe

Mirati To Challenge EMA’s Rejection Of US-Approved Krazati

Drug Was Granted Accelerated Approval By US FDA In December 2022

 
• By Neena Brizmohun

Mirati Therapeutics said it disagreed with the European Medicines Agency’s decision that its lung cancer drug did not meet its conditional marketing authorization criteria.

Concept of EMA European Medicines Agency. Drugs evaluation and quality control.
The EMA says Krazati should not be approved in the EU • Source: Shutterstock

Mirati Therapeutics is to appeal against the European Medicines Agency’s recommendation that pan-EU marketing approval should be refused for Krazati (adagrasib), the company’s US-approved treatment for KRASG12C -mutated advanced non-small cell lung cancer (NSCLC).

Mirati was seeking a conditional marketing authorization for the drug, but the EMA said today that the medicine did not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Mexico Speeds Up Market Access With Regulatory Reliance Guidelines

 
• By Francesca Bruce

Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther

Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.

Double Duty At US FDA: Tidmarsh Will Temporarily Lead Both CDER And CBER

 
• By Sarah Karlin-Smith

Just a week and a half into his tenure at the agency, the new CDER Director George Tidmarsh was also tapped to serve as acting head of CBER. Prasad’s swift ouster at CBER may point to a softening in cell and gene therapy regulation but could also portend even more scrutiny on vaccines.